Our Company was incorporated as `Gland Pharma Private Limited', a private limited company under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of our Company was changed to `Gland Pharma Limited' pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994 and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956.
Major events and milestones:
1978 Incorporation of our Company by P.V.N. Raju
2000 Set up the in-house R&D facility at Dundigal, Hyderabad
2003 Received USFDA approval for the manufacturing facility at Dundigal
2005 Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets
2007 Capital infusion of approximately ?1,000 million into the Company pursuant to private equity investment aggregating to approximately ?1,200 million with EILSF Co-Invest I LLC
2010 Launched Heparin Sodium Injection in the US
2012 Received the `Certificate of GMP Compliance of a Manufacturer' from BGV Hamburg (Germany) for our manufacturing facility at Dundigal
2014 Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam Commissioned the Pashamylaram Unit-II manufacturing facility Received the `Certificate of GMP Compliance of a Manufacturer' from MHRA (UK) for manufacturing facility at Dundigal Capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd
2016 Obtained USFDA approval for our facilities at Jawaharlal Nehru Pharma City, Visakhapatnam Obtained USFDA approval for our manufacturing facility at Pashamylaram Obtained USFDA approval for our facility at the Visakhapatnam Special Economic Zone
2017 Fosun Singapore acquired 74% stake in our Company
2018 Received ANDA approval for Enoxaparin Sodium Injection USP for the US market Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%, our first Ophthalmic product approval
2019 Filed Dexrazoxane for Injection, our first filing with the National Medical Products Administration, China, and received clinical waiver
2020
-Gland Pharma along with its partners MAIA Pharmaceucals, Inc. and Athenex Pharmaceucal Division announce the launch of a Ready-to-Use Bivalirudin Injecon in the United States of America.
2021
-Gland Pharma received approval for generic Foscarnet Sodium Injection,
Single- Dose Bag for Infusion.
-Gland Pharma receives Tentative Approval for Sugammadex Injection.
-Gland Pharma receives tentative approval for Cangrelor injection.
2022
-Gland Pharma enters into put option agreement to acquire 100% of Cenexi Group.
- Gland Pharma announces launch of Bortezomib for Injection in US market.
2024 -The Company received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection
2025 -Gland Pharma Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection, 2.5 mg/mL.
|